RAS oncogenes: the first 30 years

Malumbres, Marcos, Barbacid, Mariano·2003·Nature Reviews Cancer
DOI 10.1038/nrc1097

Cited by (1,002)

Items 301–400 of 1,002

  1. Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma
    Matthew Louis Hedberg, Corbett T. Berry, Ata S. Moshiri, Yan Xiang, Christopher J. Yeh, Cem Atillasoy, Brian C. Capell, John T. Seykora · 2022 · International Journal of Molecular Sciences
  2. Constitutively active MEK1 is sufficient to induce epithelial‐to‐mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis
    Étienne Lemieux, Sébastien Bergeron, Véronique Durand, Claude Asselin, Caroline Saucier, Nathalie Rivard · 2009 · International Journal of Cancer
  3. Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
    Chih-Chieh Chen, Tze‐Kiong Er, Yen‐Yi Liu, Jenn‐Kang Hwang, Maria Jesus Barrio, Maximiliano Rodrigo, Enrique García-Toro, Marta Herreros‐Villanueva · 2013 · PLoS ONE
  4. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: Etiopathogenic similarities, differences and paradoxes
    Miquel S. Porta, Marta Crous‐Bou, Petra A. Wark, Paolo Vineis, Francisco X. Real, Núria Malats, Ellen Kampman · 2009 · Mutation Research/Reviews in Mutation Research
  5. Global dissociation of HuR–mRNA complexes promotes cell survival after ionizing radiation
    Kiyoshi Masuda, Kotb Abdelmohsen, Mihee M. Kim, Subramanya Srikantan, Eun Kyung Lee, Kumiko Tominaga, Roza Selimyan, Jennifer L. Martindale, Xiaoling Yang, Elin Lehrmann et al. · 2011 · The EMBO Journal
  6. Conformations of KRAS4B Affected by Its Partner Binding and G12C Mutation: Insights from GaMD Trajectory-Image Transformation-Based Deep Learning
    Jianzhong Chen, Jian Wang, Wanchun Yang, Lu Zhao, Guodong Hu · 2024 · Journal of Chemical Information and Modeling
  7. Precursor lesions in pancreatic cancer: morphological and molecular pathology
    Christopher James Scarlett, Elizabeth Salisbury, Andrew Victor Biankin, James G. Kench · 2011 · Pathology
  8. Breaking news: high-speed race ends in arrest – how oncogenes induce senescence
    Raffaella Di Micco, Marzia Fumagalli, Fabrizio d’Adda di Fagagna · 2007 · Trends in Cell Biology
  9. Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer
    Yuichiro Yokoyama, Toshiaki Watanabe, Yusuke Tamura, Yoshinobu Hashizume, Kohei Miyazono, Shogo Ehata · 2017 · Cancer Research
  10. CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
    Karol A. Szlachta, Cem Kuscu, Turan Tufan, Sara J. Adair, Stephen Shang, Alex D. Michaels, Matthew G. Mullen, Natasha Lopes Fischer, Jiekun Yang, Limin Liu et al. · 2018 · Nature Communications
  11. RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth
    Depeille, Philippe, Henricks, Linda M., van de Ven, Robert A. H., Lemmens, Ed, Wang, Chih-Yang, Matli, Mary, Werb, Zena, Haigis, Kevin M., Donner, David, Warren, Robert et al. · 2015 · Nature Cell Biology
  12. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
    Tang, Daolin, Kroemer, Guido, Kang, Rui · 2021 · Molecular Cancer
  13. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
    Wenbin Li, Tian Qiu, Wenxue Zhi, Susheng Shi, Shuangmei Zou, Yun Ling, Ling Shan, Jianming Ying, Ning Lü · 2015 · BMC Cancer
  14. A Cardiac-enriched MicroRNA, miR-378, Blocks Cardiac Hypertrophy by Targeting Ras Signaling
    Raghu Sundaresan Nagalingam, Nagalingam Ravi Sundaresan, Mahesh P. Gupta, David L. Geenen, R.John Solaro, Madhu Gupta · 2013 · Journal of Biological Chemistry · Retracted
  15. Distinct functions for ERKs?
    Alison C. Lloyd · 2006 · Journal of Biology
  16. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
    Wolfram C. M. Dempke, Volker Heinemann · 2009 · European Journal of Cancer
  17. Molecular mechanism of pancreatic cancer—understanding proliferation, invasion, and metastasis
    André L. Mihaljević, Christoph W. Michalski, Helmut Friess, Jorg H. Kleeff · 2010 · Langenbeck s Archives of Surgery
  18. Selective Raf inhibition in cancer therapy
    Vladimir Khazak, Igor A. Astsaturov, Ilya G. Serebriiskii, Erica A. Golemis · 2007 · Expert Opinion on Therapeutic Targets
  19. Par‐4 inhibits Akt and suppresses Ras‐induced lung tumorigenesis
    Jayashree P. Joshi, Pablo J. Fernández-Marcos, Anita S. Galvez, Ramars Amanchy, Juan F. Linares, Ángeles Durán, Peterson Pathrose, Michael Leitges, Marta Cañamero, Manuel Collado et al. · 2008 · The EMBO Journal
  20. Targeting NRAS in Melanoma
    Fergal C. Kelleher, Grant A. McArthur · 2012 · The Cancer Journal
  21. Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
    Erin M. Coffee, Anthony C. Faber, Jatin Roper, Mark J. Sinnamon, Gautam Goel, Lily Keung, Wei Vivian Wang, Loredana Vecchione, Veerle de Vriendt, Barbara Weinstein et al. · 2013 · Clinical Cancer Research
  22. Raf-1 Cysteine-Rich Domain Increases the Affinity of K-Ras/Raf at the Membrane, Promoting MAPK Signaling
    Shuai Li, Hyunbum Jang, Jian Zhang, Ruth Nussinov · 2018 · Structure
  23. SnapShot: Ras Signaling
    Megan Cully, Julian Downward · 2008 · Cell
  24. ROS up-regulation mediates Ras-induced changes of cell morphology and motility
    Antonina Y. Alexandrova, Pavel Kopnin, Jury M. Vasiliev, Boris P. Kopnin · 2006 · Experimental Cell Research
  25. Direct Modulation of Small GTPase Activity and Function
    Philipp M. Cromm, Jochen Spiegel, Tom N. Grossmann, Herbert Waldmann · 2015 · Angewandte Chemie International Edition
  26. Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer
    Dharmalingam Subramaniam, Gaurav Kaushik, Prasad R. Dandawate, Shrikant Anant · 2017 · Current Medicinal Chemistry
  27. Targeting Ras in myeloid leukemias
    Braun, Benjamin S., Shannon, Kevin · 2008 · Clinical Cancer Research
  28. RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
    Miller, Mark Steven, Miller, Lance D. · 2012 · Frontiers in Genetics
  29. USP17 Regulates Ras Activation and Cell Proliferation by Blocking RCE1 Activity
    James F. Burrows, Alyson A. Kelvin, Cheryl McFarlane, Roberta E. Burden, Michael J. McGrattan, Michelle de la Vega, Ureshnie Govender, Derek J. Quinn, Karim Dib, Massimo Gadina et al. · 2009 · Journal of Biological Chemistry
  30. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas
    Donata Vitagliano, Giuseppe Portella, Giancarlo Troncone, A Francione, Cosmo Rossi, A Bruno, Andrea Giorgini, Sabrina Coluzzi, Tito Claudio Nappi, Jay L. Rothstein et al. · 2006 · Oncogene
  31. The cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction
    Nagasaka, K, Pim, D, Massimi, P, Thomas, M, Tomaić, V, Subbaiah, V K, Kranjec, C, Nakagawa, S, Yano, T, Taketani, Y et al. · 2010 · Oncogene
  32. Drugging K-RasG12C through covalent inhibitors: Mission possible?
    Ni, Duan, Li, Xinyi, He, Xinheng, Zhang, Hao, Zhang, Jian, Lu, Shaoyong · 2019 · Pharmacology & Therapeutics
  33. Therapeutics Targeting Mutant KRAS
    Kyaw Zin Thein, Amadeo B. Biter, David S. Hong · 2020 · Annual Review of Medicine
  34. K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function
    Blanca Alvarez-Moya, Cristina López-Alcalá, Matthias Drosten, Oriol Bachs, Neus Agell · 2010 · Oncogene
  35. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma
    Yoram Cohen, Nitza Goldenberg‐Cohen, Bruria Shalmon, Tali Shani, Shirley Oren, Ninette Amariglio, Olga Dratviman‐Storobinsky, Anna Shnaiderman-Shapiro, Ran Yahalom, Ilana Kaplan et al. · 2011 · Oral Oncology
  36. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
    Ninel Azoitei, Christopher M. Hoffmann, Jana M. Ellegast, Claudia R. Ball, Kerstin Obermayer, Ulrike Gößele, Britta Koch, Katrin Faber, Felicitas Genze, Mark G. Schrader et al. · 2012 · The Journal of Experimental Medicine
  37. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
    Matthew Dankner, Mathieu Lajoie, Dan Moldoveanu, Tan-Trieu Nguyen, Paul Savage, Shivshankari Rajkumar, Xiu Huang, Maria Lvova, Alexei I. Protopopov, Dana Vuzman et al. · 2018 · Clinical Cancer Research
  38. Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
    Jose M Baselga, Neal X. Rosen · 2008 · Journal of Clinical Oncology
  39. ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis
    Lidong Wang, Huibin Yang, Ethan V. Abel, Gina M. Ney, Phillip Lee Palmbos, Filip Bednar, Yaqing Zhang, Jacob Leflein, Meghna Waghray, Scott R. Owens et al. · 2015 · Genes & Development
  40. Genetic alterations in melanocytic tumors
    Minoru Takata, Toshiaki Saida · 2006 · Journal of Dermatological Science
  41. Spatiotemporal Organization of Ras Signaling: Rasosomes and the Galectin Switch
    Uri Ashery, Ofer Yizhar, Barak Rotblat, Galit Elad‐Sfadia, Batya Barkan, Roni Haklai, Yoel Kloog · 2006 · Cellular and Molecular Neurobiology
  42. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention
    Saswati Karmakar, Garima Kaushik, Rama Krishna Nimmakayala, Satyanarayana Rachagani, Moorthy Palanimuthu Ponnusamy, Surinder K. Batra · 2017 · Seminars in Cancer Biology
  43. The role of mitogen‐ and stress‐activated protein kinase pathways in melanoma
    Pablo Lopez‐Bergami · 2011 · Pigment Cell & Melanoma Research
  44. Tissue Transglutaminase Is an Essential Participant in the Epidermal Growth Factor-stimulated Signaling Pathway Leading to Cancer Cell Migration and Invasion
    Marc A. Antonyak, Bo Li, Andrew D. Regan, Qiyu Feng, Stephanie S. Dusaban, Richard A. Cerione · 2009 · Journal of Biological Chemistry
  45. Inhibitors of Ras–SOS Interactions
    Lu, Shaoyong, Jang, Hyunbum, Zhang, Jian, Nussinov, Ruth · 2016 · ChemMedChem
  46. Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer
    Xiaomin Zhong, Lan Zheng, Jianfeng Shen, Dongmei Zhang, Minmin Xiong, Youyou Zhang, Xinhong He, Janos Laszlo Tanyi, Feng Yang, Kathleen T. Montone et al. · 2016 · Molecular and Cellular Biology
  47. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting
    Nicolas Jonckheere, Romain Vasseur, Isabelle VAN SEUNINGEN · 2017 · Critical Reviews in Oncology/Hematology
  48. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma
    Y Zhang, Jin Kim, Adam C. Mueller, B Dey, Yue Yang, D-h Lee, Jan T. Hachmann, Sanjo Finderle, D M Park, James G. Christensen et al. · 2014 · Cell Death and Differentiation
  49. The molecular biology of colorectal carcinoma and its implications: A review
    Sanjay Harrison, Harrison Benziger · 2011 · The Surgeon
  50. Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia
    Douglas Buckner Johnson, Keiran S.M. Smalley, Jeffrey Alan Sosman · 2014 · Clinical Cancer Research
  51. Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain
    Irena Antic, Marco Biancucci, Yueming Zhu, David R. Gius, K.J.F. Satchell · 2015 · Nature Communications
  52. Oncogenes and tumor angiogenesis
    Janusz W. Rak, Joanne Yu · 2004 · Seminars in Cancer Biology
  53. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy
    Lu, Yingnian, Bellgrau, Donald, Dwyer-Nield, Lori D., Malkinson, Alvin M., Duke, Richard C., Rodell, Timothy C., Franzusoff, Alex · 2004 · Cancer Research
  54. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic
    Emmanouil Fokas, Eric O’Neill, Alex Nicolas Gordon-Weeks, Somnath Mukherjee, W. Gillies McKenna, Ruth J. Muschel · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  55. Identification of Essential Interacting Elements in K-Ras/Calmodulin Binding and Its Role in K-Ras Localization
    Cristina López-Alcalá, Blanca Alvarez-Moya, Priam Villalonga, Marı́a Calvo, Oriol Bachs, Neus Agell · 2008 · Journal of Biological Chemistry
  56. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation
    Yuji Kubota, Pauline O'Grady, Haruo Saito, Mutsuhiro Takekawa · 2011 · Nature Cell Biology
  57. Nras in melanoma: Targeting the undruggable target
    Mario Mandalà, Barbara Merelli, Daniela Massi · 2014 · Critical Reviews in Oncology/Hematology
  58. The PTEN Phosphatase Controls Intestinal Epithelial Cell Polarity and Barrier Function: Role in Colorectal Cancer Progression
    Marie‐Josée Langlois, Sébastien Bergeron, Gérald Bernatchez, François Boudreau, Caroline Saucier, Nathalie Perreault, Julie C. Carrier, Nathalie Rivard · 2010 · PLoS ONE
  59. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
    Jennifer S. Carew, Claudia M. Espitia, W Zhao, Kevin R. Kelly, Matt C. Coffey, James W. Freeman, Steffan T. Nawrocki · 2013 · Cell Death and Disease
  60. Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities
    Andrew Xiuxuan Zhu, Aram F. Hezel · 2011 · Hepatology
  61. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma
    Daniela Massi, Lisa Simi, Elisa Sensi, Gianna Baroni, Gongda Xue, Cristian Scatena, Adele Caldarella, Pamela Pinzani, Gabriella Fontanini, Alessandra Carobbio et al. · 2014 · Modern Pathology
  62. Opportunities and challenges of protein-based targeted protein degradation
    Fangfang Shen, Laura M. K. Dassama · 2023 · Chemical Science
  63. Heparanase Cooperates with Ras to Drive Breast and Skin Tumorigenesis
    Ilanit Boyango, Uri Barash, Inna Naroditsky, Jin‐Ping Li, Edward Hammond, Neta Ilan, Israël Vlodavsky · 2014 · Cancer Research
  64. Menin determines K-RAS proliferative outputs in endocrine cells
    Chester E. Chamberlain, David W. Scheel, Kathleen McGlynn, Hail Kim, Takeshi Miyatsuka, Juehu Wang, Vinh Q Nguyen, Shuhong Zhao, Anastasia Mavropoulos, Aswin Abraham et al. · 2014 · Journal of Clinical Investigation
  65. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors
    Laure Voisin, Catherine Julien, Stéphanie Duhamel, Kailesh Gopalbhai, Isabelle Claveau, Marc K. Saba-El-Leil, Ian Gaël Rodrigue‐Gervais, Louis Arthur Gaboury, Daniel Lamarre, Mark Basik et al. · 2008 · BMC Cancer
  66. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations
    Ellen Denayer, Koenraad Devriendt, Thomy J.L. de Ravel, Griet Van Buggenhout, Eric Smeets, Inge François, Yves Sznajer, Margarita Craen, Georgios Leventopoulos, Léon Mutesa et al. · 2009 · Genes Chromosomes and Cancer
  67. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells
    D. Xu, Stephen A. Allsop, Sam M. Witherspoon, J. L. Snider, Jen Jen Yeh, James J. Fiordalisi, C. de B. White, D. Williams, Adrienne D. Cox, Antonio T. Baines · 2011 · Carcinogenesis
  68. Frequencies and Prognostic Role of KRAS and BRAF Mutations in Patients With Localized Pancreatic and Ampullary Adenocarcinomas
    Schultz, Nicolai Aagaard, Roslind, Anne, Christensen, Ib J., Horn, Thomas, Høgdall, Estrid, Pedersen, Lisbeth N., Kruhøffer, Mogens, Burcharth, Flemming, Wøjdemann, Morten, Johansen, Julia S. · 2012 · Pancreas
  69. Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line
    Breanne D.W. Karanikolas, Marxa Leão Figueiredo, Lily Wu · 2009 · Molecular Cancer Research
  70. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors
    Osama E. Rahma, J. Michael Hamilton, Malgorzata E. Wojtowicz, Omar Dakheel, Sarah A. Bernstein, David J. Liewehr, Seth M. Steinberg, Samir N. Khleif · 2014 · Journal of Translational Medicine
  71. A seven-gene signature predicts overall survival of patients with colorectal cancer
    Huarong Chen, Xiaoqiang Sun, Weiting Ge, Yun Qian, Rui Bai, Shu Sen Zheng · 2016 · Oncotarget
  72. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution
    Khurum Hayat Khan, Nicola Valeri, Charles Dearman, Sheela Rao, David J. Watkins, Naureen Starling, Ian Chau, David Cunningham · 2019 · Critical Reviews in Oncology/Hematology
  73. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer
    Seth, R, Crook, S, Ibrahem, S, Fadhil, W, Jackson, D, Ilyas, M · 2009 · Gut
  74. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
    Santarpia, Mariacarmela, Ciappina, Giuliana, Spagnolo, Calogera Claudia, Squeri, Andrea, Passalacqua, Maria Ilenia, Aguilar, Andrés, Gonzalez-Cao, Maria, Giovannetti, Elisa, Silvestris, Nicola, Rosell, Rafael · 2023 · Translational Lung Cancer Research
  75. Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor
    Eun Young Song, Navneet Kaur, Mi-Young Park, Yinglan Jin, Kyeong Lee, Guncheol Kim, Ki Youn Lee, Jee Sun Yang, Jae Hong Shin, Ky-Youb Nam et al. · 2007 · European Journal of Medicinal Chemistry
  76. The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
    Guégan, Jean-Philippe, Frémin, Christophe, Baffet, Georges · 2012 · International Journal of Hepatology
  77. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells
    Jianghong Man, Bing Liang, Yue-Xi Gu, Tao Zhou, Ai-Ling Li, Tao Li, Bao-Feng Jin, Bing Bai, Hai‐Ying Zhang, Wei-Na Zhang et al. · 2010 · Journal of Clinical Investigation
  78. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome
    Shinichi Inoue, Mitsuji Moriya, Yusuke Watanabe, Sachiko Miyagawa‐Tomita, Tetsuya Niihori, Daiju Oba, Masao Ono, Shigeo Kure, Toshihiko Ogura, Yoichi Matsubara et al. · 2014 · Human Molecular Genetics
  79. The roles of microRNAs in tumorigenesis and angiogenesis.
    Weining Yang, Daniel Y Lee, Yaacov Ben‐David · 2011 · PubMed Central
  80. The intermediate-activityL597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway
    Catherine Andreadi, Lai-Kay Maggie Cheung, Susan M. Giblett, Bipin PATEL, Hong Jin, Kathryn Mercer, Tamihiro Kamata, Pearl Lee, Alexander G. Williams, Martin McMahon et al. · 2012 · Genes & Development
  81. Prevalence of BRAF V600 in glioma and use of BRAF Inhibitors in patients with BRAF V600 mutation-positive glioma: systematic review
    Lily Andrews, Zak A Thornton, Saanwalshah Samir Saincher, Ian Y Yao, Sarah Dawson, Luke A. McGuinness, Hayley E. Jones, Sarah Jefferies, Susan C Short, Hung‐Yuan Cheng et al. · 2021 · Neuro-Oncology
  82. Various p53 mutant types differently regulate the Ras circuit to induce a cancer-related gene signature
    Hilla Solomon, Yosef Buganim, Leslie Pomeraniec, Tsevi Beatus, Yael Assia, Ira Kogan-Sakin, Shalom Madar, Ido Goldstein, Ran Brosh, Eyal Kalo et al. · 2012 · Journal of Cell Science
  83. Personalized Therapy for Lung Cancer
    Andre Luis Moreira, Juliana Eng · 2014 · CHEST Journal
  84. Quantitative evaluation of RASSF1Amethylation in the non-lesional, regenerative and neoplastic liver
    Sonia Di Gioia, Paolo Pietro Bianchi, Annarita Destro, Fabio Grizzi, Alberto Malesci, Luigi Laghi, Massimo Levrero, Alberto Morabito, Massimo G. Roncalli · 2006 · BMC Cancer
  85. The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors
    Henning Stehr, Seon-Hi J Jang, José M. Duarte, Christoph Wierling, Hans Rudolf Lehrach, Michael Lappé, Bodo M. H. Lange · 2011 · Molecular Cancer
  86. Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
    Francesco Marampon, Carmela Ciccarelli, BIANCA MARIA ZANI · 2019 · International Journal of Molecular Sciences
  87. RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it
    Bruce D. Gelb, Marco Tartaglia · 2011 · Journal of Clinical Investigation
  88. Noonan syndrome: Psychological and psychiatric aspects
    Willem M. A. Verhoeven, Ellen Wingbermühle, J.I.M. Egger, Ineke van der Burgt, S. Tuinier · 2007 · American Journal of Medical Genetics Part A
  89. Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules
    Elizabeth J. de Koster, Lioe‐Fee de Geus‐Oei, Olaf M. Dekkers, Ilse van Engen‐van Grunsven, Jaap F. Hamming, Eleonora P.M. Corssmit, Hans M. Morreau, Abbey Schepers, Johannes W. A. Smit, Wim J.G. Oyen et al. · 2018 · Endocrine Reviews
  90. Dynamics of Membrane-Bound G12V-KRAS from Simulations and Single-Molecule FRET in Native Nanodiscs
    Priyanka Prakash, Douglas B. Litwin, Liang Hong, Suparna Sarkar‐Banerjee, Drew M. Dolino, Yong Zhou, John F. Hancock, Vasanthi Jayaraman, Alemayehu Abebe Gorfe · 2018 · Biophysical Journal
  91. Dose-Dependent Inhibition of Thyroid Differentiation by RAS Oncogenes
    Gabriella De Vita, Lisa Bauer, Vânia Maria Corrêa da Costa, Mario De Felice, Maria Giuseppina Baratta, Marta De Menna, Roberto Di Lauro · 2004 · Molecular Endocrinology
  92. 1,25‐Dihydroxy vitamin D prevents tumorigenesis by inhibiting oxidative stress and inducing tumor cellular senescence in mice
    Lulu Chen, Renlei Yang, Wanxin Qiao, Xiaoqin Yuan, Shui Wang, David Goltzman, Dengshun Miao · 2018 · International Journal of Cancer
  93. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
    James Larkin, Fisher · 2012 · Cancer Management and Research
  94. Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells
    Carles Barceló, Julia Etchin, Marc R. Mansour, Takaomi Sanda, Mireia Morell, Victor Javier Sanchez-Arevalo Lobo, Francisco X. Real, Gabriel Capellá, Josep Marı́a Estanyol, Montserrat Jaumot et al. · 2014 · Gastroenterology
  95. H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling
    Alessandro Rimessi, Saverio Marchi, Simone Patergnani, Paolo Pinton · 2013 · Oncogene
  96. Ras GTPase-Activating Protein Regulation of Actin Cytoskeleton and Hyphal Polarity in Aspergillus nidulans
    Laura Harispe, Cecilia Portela, Claudio Scazzocchio, Miguel Angel Peñalva, Lisette Gorfinkiel · 2007 · Eukaryotic Cell
  97. K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function
    Shufen Cao, Stacey Chung, SoonJeung Kim, Zhenlu Li, Danny Manor, Matthias Buck · 2019 · Journal of Biological Chemistry
  98. Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD)
    Quentin Neven, Cécile Boulanger, Annelyse Bruwier, Maëlle de Ville de Goyet, Isabelle Meyts, Leen Moens, An Van Damme, Bénédicte Brichard · 2020 · Journal of Clinical Immunology
  99. Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
    James Cregg, Kristof Pota, Aidan C.A. Tomlinson, Jason K. Yano, Abby Marquez, Yang Liu, Christopher J. Schulze, Kyle J. Seamon, Matthew T. Holderfield, Xing Wei et al. · 2025 · Journal of Medicinal Chemistry
  100. A Functional Screen Reveals an Extensive Layer of Transcriptional and Splicing Control Underlying RAS/MAPK Signaling in Drosophila
    Dariel Ashton‐Beaucage, Christian M. Udell, Patrick Gendron, Malha Sahmi, Martin Lefrançois, Caroline Baril, Anne-Sophie Guenier, Jean Duchaine, Daniel Lamarre, Sébastien Lemieux et al. · 2014 · PLoS Biology